TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03824886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of skin care algorithm
Description: Implementation of structured and standardized skin care regimen
Study: NCT03916367

Intervention type: RADIATION
Intervention: CT-guided Radioactive I-125 Seeds Implantation
Description: The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring.
Study: NCT02658734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: 3.6 mg/kg intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle, repeated every 3 weeks
Study: NCT04238143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Stromal Vascular Fraction (tSVF) Arm 1
Description: Harvesting subcutaneous tSVF with sterile, disposable microcannula system

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP Concentrate Arm 1
Description: Preparation of PRP Concentrate via sterile Terumo-Harvest System

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Stromal Vascular Fraction (tSVF) Arm 2
Description: Harvesting subcutaneous tSVF with sterile, disposable microcannula system

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP Concentrate Arm 2
Description: Preparation of PRP Concentrate via sterile Terumo-Harvest System

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cellular Stromal Vascular Fraction (cSVF) Arm 2
Description: Isolation-Concentration of cSVF via sterile enzymatic digestion (Liberase TM, Sterile Roche)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cellular Stromal Vascular Fraction (cSVF) Arm 3
Description: Isolation-Concentration of cSVF via sterile enzymatic digestion (Liberase TM, Sterile Roche)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sterile Normal Saline (IV Solution)
Description: Suspension of cSVF in 500 cc Sterile Normal Saline (IV Solution)
Study: NCT02728583

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Margarine enriched with plant sterols and fish oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo margarine
Study: NCT04083469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Led Peer-Elected Intervention
Description: The intervention will be given to students by a peer opinion leader that the students in the audience elected. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adult-Led Intervention
Description: The intervention will be given to students by an adult. The intervention is a version of CATCH My Breath curriculum that has been modified to match the Peer-Led Intervention curriculum but is able to be administered by an adult.
Study: NCT03621293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modulation of Inspired Fraction of Oxygen (FiO2)
Description: In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modulation of Inspired Fraction of Oxygen (FiO2)
Description: In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient.
Study: NCT03949660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation for blood pressure without stand
Description: Consists of 80 daily training sessions using epidural stimulation optimized for blood pressure for up to 6 hours of stimulation a day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation for blood pressure with stand
Description: Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation for trunk and core without stand
Description: Consists of 80 daily training sessions using epidural stimulation optimized for trunk/core/voluntary function for up to 6 hours of stimulation a day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation for trunk or core with stand
Description: Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
Study: NCT00675506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone releasing hormone (GHRH) 1-44
Description: 2-mg sub-cutaneous injections once daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2-mg sub-cutaneous injections once daily for 12 months
Study: NCT02132533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Nifedipine 20 mg orally, then nifedipine 20 mg orally after 90 minutes if still contracting. Continue nifedipine 20 mg orally every 4 hours after the first dose for 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo orally, then placebo orally after 90 minutes if still contracting. Continue placebo orally every 4 hours after the first dose for 48 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual evaluation, monitoring and care for women with preterm labor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual evaluation, monitoring and care for women with preterm labor.
Study: NCT01183650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 mg, administered orally, daily for 10 days
Study: NCT00299195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulindac
Description: Sulindac 150 mg po bid x 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid x 24 weeks
Study: NCT03097003

Intervention type: DRUG
Intervention: Apremilast
Description: Psoriasis patients treated with Otezla® (Apremilast) in Belgium
Study: NCT03650660

Intervention type: OTHER
Intervention: Trans-thoracic ultrasound
Description: Trans-thoracic ultrasound performed by an expert and a non-expert
Study: NCT01306175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin plus BI 10773
Description: Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin 0.5 mg as single dose
Study: NCT04435392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Cream
Description: Subjects in each group were scheduled to give the drug for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Cream
Description: Subjects in each group were scheduled to give the drug for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Cream
Description: Subjects in each group were scheduled to give the drug for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Cream
Description: Subjects in each group were scheduled to give the drug for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Cream
Description: Subjects in each group were scheduled to give the drug for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Cream
Description: Subjects in each group were scheduled to give the drug for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00786201

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion every 4 weeks, from Week 0 through Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 888 1 mg/kg
Description: IV infusion every 4 weeks, from Week 0 through Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 888 5 mg/kg
Description: IV infusion every 4 weeks, from Week 0 through Week 48

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTO 888 15 mg/kg
Description: IV infusion every 4 weeks, from Week 0 through Week 48
Study: NCT02707419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Video of the exercises

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: video of nature scenes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Mobilization, exercises and transfer practice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: Mobilization, exercises and transfer practice.
Study: NCT04136652

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser- treatment (DEKA SmartXide2 Laser System, MonaLisa Touch
Description: women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia. A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault. A burst of laser pulses is transmitted through the probe and deflected at 90degrees in four directions towards the vaginal wall, then rotated 45degree for a second burst of pulses. Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus. Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: CO2 laser- treatment (DEKA SmartXide2 Laser System, MonaLisa Touch
Description: women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia. A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault. A burst of laser pulses is transmitted through the probe and deflected at 90degrees in four directions towards the vaginal wall, then rotated 45degree for a second burst of pulses. Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus. Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.
Study: NCT04175418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Program
Description: The exercise program in this group includes aerobic (walking) training and exercises to strengthen the upper and lower extremities and trunk muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Education Program
Description: The exercise program in this group includes aerobic (walking) training and home exercises to strengthen the upper and lower extremities and trunk muscles.
Study: NCT02125123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement and Counseling
Description: Ready-to-feed nutritional supplement and dietary counseling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Dietary counseling
Study: NCT04083469

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer-Led Non-Elected Intervention
Description: The intervention will be given to students by a peer opinion leader that was elected by other students. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
Study: NCT03868748

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-arbutin
Description: Beta-arbutin capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-arbutin
Description: Beta-arbutin capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules containing non-medicinal ingredients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules containing non-medicinal ingredients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules containing non-medicinal ingredients
Study: NCT00704444

Intervention type: DRUG
Intervention: Ezetimibe
Description: Ezetimibe, 10-mg tablets

Intervention type: DRUG
Intervention: Ezetimibe + other lipid-lowering medication(s)
Description: Ezetimibe, 10-mg tablets + other lipid-lowering medication(s), as prescribed by attending physician
Study: NCT00810446

Intervention type: DRUG
Intervention: rifabutin
Description: Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.~3.Inhibition of disseminated Mycobacterium avium complex (MAC) disease associated with HIV infections : The usual adult dosage for oral use is 300 mg of rifabutin once daily..
Study: NCT02688998

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: venous access PORT or PICC
Description: Participants will receive a venous access prior to starting chemotherapy
Study: NCT01210677

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone 0.5 mg/Kg orally per day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 0.5 mg/Kg orally per day for 3 months
Study: NCT03963050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: The ET program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: The ET program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.
Study: NCT00211237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon Kyphoplasty
Description: Ballon Kyphoplasty is a minimally invasive technique aimed at reduction of VCFs using KyphX® Inflatable Bone Tamps followed by fracture fixation with KyphX® HV-R™ Bone Cement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Surgical Management
Description: Non-surgical treatment includes, but is not limited to, the following: back brace, pain medication, physical therapy, walking aids, bed rest, and radiation treatment.
Study: NCT00493337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: advanced adherence counseling+reminder
Study: NCT03030105

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BPN14770 placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BPN14770 placebo
Description: placebo
Study: NCT03963050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training + Cognitive Training
Description: ET: The intervention program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.~CT: The intervention program will be configured as a cognitive rehabilitation and mainly memory rehabilitation: the participants will be trained in practicing restorative and compensatory mnemonic techniques, such as visual imagery, face-name association, calendar, notes and prompts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training + Cognitive Training
Description: ET: The intervention program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.~CT: The intervention program will be configured as a cognitive rehabilitation and mainly memory rehabilitation: the participants will be trained in practicing restorative and compensatory mnemonic techniques, such as visual imagery, face-name association, calendar, notes and prompts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: NO changes in lifestyle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: NO changes in lifestyle
Study: NCT03581734

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Polio Vaccine
Description: OPV is a mixture of live attenuated poliovirus strains of each of the three serotypes, selected by their ability to mimic the immune response following infection with wild polioviruses, but with a significantly reduced incidence of spreading to the central nervous system.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine
Description: OPV is a mixture of live attenuated poliovirus strains of each of the three serotypes, selected by their ability to mimic the immune response following infection with wild polioviruses, but with a significantly reduced incidence of spreading to the central nervous system.
Study: NCT03030105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: comparator
Study: NCT03581734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Cholera Vaccine
Description: Bivalent, Killed, Whole Cell Oral Cholera Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Cholera Vaccine
Description: Bivalent, Killed, Whole Cell Oral Cholera Vaccine
Study: NCT02197286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: One capsule containing 4,000 IU of Cholecalciferol, per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of a single gelatin placebo capsule.
Study: NCT05860439

Intervention type: PROCEDURE
Intervention: Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)
Description: Patients previously treated were reassessed for long-term follow-up.

Intervention type: PROCEDURE
Intervention: Polidocanol 0,2% + Hypertonic Glucose 70% (PDHG)
Description: Patients previously treated were reassessed for long-term follow-up.
Study: NCT00875199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Prize-based contingency management for weight loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight loss manual-guided individual therapy sessions
Description: once weekly counseling session with research staff
Study: NCT03030105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil placebo
Description: placebo
Study: NCT02389790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303
Study: NCT00282906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hybrid PET-CT imaging system
Description: 15 mCi of FDG
Study: NCT03676296

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Puerarin
Description: Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puerarin
Description: Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks
Study: NCT02656290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards Pericardial Aortic Bioprosthesis Model 11000A
Description: Edwards Aortic Bioprosthesis Model 11000A in the pulmonary position; a trileaflet bioprosthesis comprised of bovine pericardium
Study: NCT02852200

Intervention type: OTHER
Intervention: SEGAm
Study: NCT01780402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand feeding techniques
Description: Direct hand feeding technique: When the feeding assistant holds the object (e.g., fork, spoon, cup) intended to provide food or fluids to the PWD without any active involvement on the part of the PWD.~Hand-over-hand feeding technique: Occurs when the PWD is holding the object (e.g., fork, spoon, cup) in an attempt to feed/ drink for themselves. If the PWD has trouble with this activity, the feeding assistant puts his or her hand over the hand of the PWD, in an effort to guide/ support/ assist the PWD with the activity.~Hand-under-hand feeding technique: Occurs when the feeding assistant holds the object (e.g., fork, spoon, cup) and places the PWD hand over the top of their hand; therefore, the feeding assistants hand is under the hand of the PWD in a more supportive position.
Study: NCT02584127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high reinforcement cessation program
Description: Six-step, self-administered, internet smoking cessation program with high reinforcement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low reinforcement cessation program
Description: Six-step, self-administered, internet smoking cessation program with low reinforcement.